ZEAL Zealand Pharma A/S

24.88
0  0%
Previous Close 24.88
Open
Price To Book 6.2
Market Cap 889,091,065
Shares 35,742,067
Volume 828
Short Ratio
Av. Daily Volume 8,648

NewsSee all news

  1. Zealand Pharma completes subscription of new shares and registration of capital increase

    Company announcement – No. 33 / 2019 Zealand Pharma completes subscription of new shares and registration of capital increase Copenhagen, September 11, 2019 – With reference to the company announcement no. 30/2019

  2. Zealand Pharma announces private placement and directed issue of new shares with expected gross proceeds of DKK 559.6 million

    Company announcement – No. 30 / 2019 A total of 3,975,000 new shares (the "New Shares") have been subscribed for with expected gross proceeds of approx. DKK 559.6 million The private placement and directed

  3. Boehringer Ingelheim and Zealand Pharma Advance Dual-Acting GLP-1/glucagon Agonist BI 456906 to Phase 2 Clinical Testing in Obesity/Diabetes

    The dual acting GLP-1/glucagon peptide BI 456906 is a part of Boehringer Ingelheim's pipeline portfolio in obesity and diabetes The Phase 2 trial for BI 456906 is expected to be initiated in late 2019 and will

  4. Zealand Pharma to attend Morgan Stanley 17th Annual Global Healthcare Conference

    Press release – No. 19 / 2019   Copenhagen, August 29, 2019 – Zealand Pharma Chief Executive Officer Emmanuel Dulac will attend the Morgan Stanley 17th Annual Global Healthcare Conference on September 10, 2019 in

  5. Zealand Pharma appoints Matthew Dallas as new Chief Financial Officer

    Company announcement – No. 27 / 2019   Copenhagen, August 28, 2019 – Zealand Pharma A/S ("Zealand") (NASDAQ:ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 trial initiation announced March 6, 2019.
Dasiglucagon
Congenital hyperinsulinism
Phase 3 data released September 18, 2018. Endpoints met.
Dasiglucagon
Severe hypoglycemia in diabetes
Phase 3 trial met primary endpoint - March 2018.
Dasiglucagon
Severe hypoglycemia in diabetes
Phase 3 data due 2020.
Glepaglutide
Short bowel syndrome
Phase 3 data due September 2019.
Dasiglucagon
Severe hypoglycemia in diabetes - children
Phase 3 trial to commence 2019.
Dasiglucagon dual-hormone pump therapy
Type 1 Diabetes
Phase 3 commencement of enrolment announced May 7, 2019.
Glepaglutide - extension trial
Short bowel syndrome
Phase 1b data due 2019.
GLP1/Glu dual agonist
Obesity / diabetes
Phase 1 initiation of dosing announced June 26, 2019.
ZP7570
Short bowel syndrome (SBS)

Latest News

  1. Zealand Pharma completes subscription of new shares and registration of capital increase

    Company announcement – No. 33 / 2019 Zealand Pharma completes subscription of new shares and registration of capital increase Copenhagen, September 11, 2019 – With reference to the company announcement no. 30/2019

  2. Zealand Pharma announces private placement and directed issue of new shares with expected gross proceeds of DKK 559.6 million

    Company announcement – No. 30 / 2019 A total of 3,975,000 new shares (the "New Shares") have been subscribed for with expected gross proceeds of approx. DKK 559.6 million The private placement and directed

  3. Boehringer Ingelheim and Zealand Pharma Advance Dual-Acting GLP-1/glucagon Agonist BI 456906 to Phase 2 Clinical Testing in Obesity/Diabetes

    The dual acting GLP-1/glucagon peptide BI 456906 is a part of Boehringer Ingelheim's pipeline portfolio in obesity and diabetes The Phase 2 trial for BI 456906 is expected to be initiated in late 2019 and will

  4. Zealand Pharma to attend Morgan Stanley 17th Annual Global Healthcare Conference

    Press release – No. 19 / 2019   Copenhagen, August 29, 2019 – Zealand Pharma Chief Executive Officer Emmanuel Dulac will attend the Morgan Stanley 17th Annual Global Healthcare Conference on September 10, 2019 in

  5. Zealand Pharma appoints Matthew Dallas as new Chief Financial Officer

    Company announcement – No. 27 / 2019   Copenhagen, August 28, 2019 – Zealand Pharma A/S ("Zealand") (NASDAQ:ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and

  6. Zealand Pharma relocates headquarters to accommodate growth

    Press Release – No. 18 / 2019 Copenhagen, August 27, 2019 – Zealand Pharma A/S ("Zealand") (NASDAQ:ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of